NASDAQ · PRTA
Healthcare · Biotechnology
$9.26
Down-$0.18 (-1.94%)
Updated Aug 13, 2026, 9:10 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PRTA closed at $9.26 after 21 trading sessions, up 9.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $9.22 | $9.31 | $9.09 | $9.26 | 274.93K |
| Aug 11, 2026 | $9.12 | $9.285 | $8.862 | $9.22 | 475.25K |
| Aug 10, 2026 | $8.76 | $9.17 | $8.53 | $9.12 | 713.69K |
| Aug 7, 2026 | $8.54 | $8.85 | $8.04 | $8.76 | 481.88K |
| Aug 6, 2026 | $8.50 | $8.7664 | $8.33 | $8.58 | 418.69K |
| Aug 5, 2026 | $8.49 | $8.735 | $8.405 | $8.49 | 489.49K |
| Aug 4, 2026 | $8.33 | $8.58 | $8.33 | $8.49 | 329.91K |
| Aug 3, 2026 | $8.17 | $8.38 | $8.04 | $8.33 | 566K |
| Jul 31, 2026 | $8.41 | $8.51 | $8.00 | $8.12 | 545.49K |
| Jul 30, 2026 | $8.50 | $8.555 | $8.255 | $8.41 | 502.23K |
| Jul 29, 2026 | $8.45 | $8.68 | $8.39 | $8.56 | 641.22K |
| Jul 28, 2026 | $8.70 | $8.78 | $8.36 | $8.56 | 802.26K |
| Jul 27, 2026 | $8.88 | $9.13 | $8.66 | $8.70 | 704.71K |
| Jul 24, 2026 | $8.54 | $8.825 | $8.35 | $8.75 | 576.84K |
| Jul 23, 2026 | $8.27 | $8.625 | $8.23 | $8.53 | 532.21K |
| Jul 22, 2026 | $8.69 | $8.79 | $8.43 | $8.44 | 542.55K |
| Jul 21, 2026 | $8.72 | $8.81 | $8.51 | $8.75 | 647.64K |
| Jul 20, 2026 | $8.66 | $8.85 | $8.545 | $8.67 | 549.63K |
| Jul 17, 2026 | $8.40 | $8.7993 | $8.275 | $8.66 | 408.39K |
| Jul 16, 2026 | $8.40 | $8.66 | $8.075 | $8.47 | 659.66K |
| Jul 15, 2026 | $8.58 | $8.63 | $8.42 | $8.43 | 504.69K |
The latest Smart Investors Daily articles mentioning PRTA.
PRTA research
Company profile and research snapshot.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2026 | Citizens | Market Outperform | — |
| Feb 20, 2026 | RBC Capital | Sector Perform | — |
| Dec 1, 2025 | Citizens | Market Outperform | — |
| Nov 7, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of $(1.73) per share from
ChartMill · Aug 7, 2026
Prothena Q2: revenue $1M misses $28.9M consensus, but adj EPS -$0.32 beats -$0.40. Cost cuts narrow loss; FY cash guidance reiterated.
Yahoo · Jul 9, 2026
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
Benzinga · Feb 20, 2026
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $11 to $12.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRTA.
